1.96

3.43% 0.065

Pre-market: 1.96

Cardiol Therapeutics Inc (CRDL)

Overview News Price History Option Chain Why CRDL Down? Discussions Forecast

Cardiol Therapeutics Inc stock is traded at $1.96, with a volume of 1.72M. It is up +3.43% in the last 24 hours and up +61.98% over the past month. Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Previous Close:

$1.895

Open:

$1.92

24h Volume:

1.72M

Relative Volume:

2.39

Market Cap:

$228.97M

Revenue:

Net Income/Loss:

$-26.33M

P/E Ratio:

-6.9405

EPS:

-0.2824

Net Cash Flow:

$-17.65M

1W Performance:

+28.95%

1M Performance:

+61.98%

6M Performance:

+92.16%

1Y Performance:

+71.93%

1-Day Range:

$1.86

$1.965

1-Week Range:

$1.49

$1.965

52-Week Range:

$0.88

$1.965

Cardiol Therapeutics Inc Stock (CRDL) Company Profile

Name

Cardiol Therapeutics Inc

Sector

Healthcare (1078)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

CRDL's Discussions on Twitter

Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDL Cardiol Therapeutics Inc	1.96	221.38M	0	-26.33M	-17.65M	-0.2824
TAK Takeda Pharmaceutical Co Adr	18.34	57.64B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	37.47	42.63B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.87	42.75B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	76.68	30.56B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	529.14	22.23B	3.17B	1.29B	1.01B	27.09

Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Initiated	H.C. Wainwright	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jun-26-24	Initiated	ROTH MKM	Buy
Apr-22-24	Initiated	H.C. Wainwright	Buy

Cardiol Therapeutics Inc Stock (CRDL) Latest News

Aug 19, 2026

Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca

Aug 19, 2026

Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome

Aug 19, 2026

Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - Vinanet

Aug 19, 2026

Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca

Aug 19, 2026

Aug 18, 2026

What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome

Aug 18, 2026

Aug 17, 2026

Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - Vinanet

Aug 17, 2026

Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat

Aug 17, 2026

CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo

Aug 17, 2026

Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca

Aug 17, 2026

Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat

Aug 17, 2026

Aug 15, 2026

Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat

Aug 15, 2026

Aug 14, 2026

MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan

Aug 14, 2026

Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome

Aug 14, 2026

Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome

Aug 14, 2026

Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca

Aug 14, 2026

Aug 13, 2026

Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Aug 12, 2026

Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks

Aug 12, 2026

Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Aug 12, 2026

Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan

Aug 12, 2026

Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media

Aug 12, 2026

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat

Aug 12, 2026

Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome

Aug 12, 2026

Aug 11, 2026

Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria

Aug 11, 2026

Aug 10, 2026

Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca

Aug 10, 2026

Cardiol Therapeutics (CRDL) Gains 1.76% to $1.45, Holding Above Key SupportBPI Bull Correction - Vinanet

Aug 10, 2026

Aug 07, 2026